Dianabol (Methandrostenolone): A Complete Research Guide

Methandrostenolone — marketed historically as Dianabol — is one of the most extensively characterized oral anabolic-androgenic steroids (AAS) in the published literature, first synthesized by John Ziegler and introduced by Ciba in 1958. Six decades of clinical, athletic, and forensic investigation have produced a reasonably coherent pharmacological profile, but the compound remains poorly suited to long-duration use because of its 17-alpha-alkylated structure. This guide summarizes what researchers have reported about its pharmacokinetics, typical protocol structures used in the research literature, and the hepatic and cardiovascular risk profile that constrains how the compound is studied.

Pharmacology and Structure

Methandrostenolone is chemically 17α-methyl-17β-hydroxy-1,4-androstadien-3-one — a testosterone derivative carrying two structural modifications. The first is the 1,2-double bond in the A-ring, which reduces androgenicity relative to the parent testosterone molecule and partially decouples its androgenic and anabolic activity. The second is the 17-alpha-methyl group, a modification shared with most orally active AAS (including oxandrolone, stanozolol, and oxymetholone) that blocks first-pass hepatic metabolism and allows clinically meaningful plasma levels after oral dosing.

Binding-affinity work places methandrostenolone's interaction with the androgen receptor (AR) in a moderate range — lower than dihydrotestosterone and trenbolone, but clearly active. Reported anabolic:androgenic ratios derived from classic rat levator ani and ventral-prostate bioassays place the compound at roughly 90–210 : 40–60 relative to testosterone's 100:100 baseline, though such ratios are considered historical shorthand rather than clinically predictive.

Two secondary mechanisms contribute to the compound's characteristic effects. Methandrostenolone is a substrate for aromatase, though with reduced efficiency compared with testosterone; the primary aromatized metabolite, 17α-methylestradiol, is poorly cleared and exerts estrogenic activity at the receptor. This accounts for the water retention, gynecomastia risk, and blood-pressure elevation consistently reported in the literature. Second, methandrostenolone shows relatively weak 5α-reductase conversion, meaning its androgenic profile in tissues such as scalp and prostate is modest compared with testosterone itself.

The elimination half-life has been reported in the 3–6 hour range across multiple pharmacokinetic studies, with most sources clustering near 4.5 hours. This short window drives the divided-dose protocols seen throughout the research literature.

Dosing and Administration in the Research Literature

Because of the short plasma half-life, protocols described in published case reports and anti-doping literature typically split daily intake across the day rather than administering a single dose. Total daily intakes reported in observational surveys of AAS-using athletes range widely, but cluster in the 20–50 mg per day band, with 30 mg per day described as a common mid-point in the retrospective self-report literature.

A representative split structure appears frequently in case-report methodology sections:

• 20 mg/day: 10 mg on waking, 10 mg eight hours later
• 30 mg/day: 10 mg three times daily with meals
• 40–50 mg/day: 10 mg every 4–5 waking hours

Higher daily intakes — 70 mg and above — appear in the bodybuilding literature but are associated in case-report series with disproportionate increases in hepatic and cardiovascular markers relative to the lean-mass gains reported, which is why the 20–50 mg band is typically cited as the informative dose range in more recent observational studies.

Timing around feeding remains unresolved. Earlier guidance in the pharmacology literature suggested fasted administration for faster absorption; later work noted that co-administration with food did not meaningfully alter peak plasma concentrations but did reduce reports of gastric irritation. Current convention in the self-report literature is to dose with meals.

The Kickstart Protocol

The most frequently described research context for methandrostenolone is the so-called "kickstart" — a 4–6 week oral front-load layered onto the opening phase of a longer testosterone-based protocol. The pharmacological rationale is straightforward. Injected testosterone esters (enanthate, cypionate) require 3–5 weeks to reach steady-state plasma concentrations, creating a lag between protocol initiation and detectable anabolic effect. An orally active compound with a short half-life produces measurable androgen-receptor engagement within days, effectively bridging the kinetic gap.

Typical kickstart structures documented in published athlete self-reports include:

• Weeks 1–4: methandrostenolone 30 mg/day + testosterone enanthate 400–500 mg/week
• Weeks 1–6: methandrostenolone 25 mg/day + testosterone cypionate 500 mg/week
• Weeks 5 onward: testosterone monotherapy continues while methandrostenolone is discontinued

The 4–6 week ceiling is not arbitrary. Hepatic stress markers (ALT, AST, GGT, alkaline phosphatase) typically begin rising within the first 14 days of 17-alkylated oral administration and, in the published case series, reach levels that clinicians would flag as concerning by week 5–6 even at moderate doses. Extending the oral phase beyond six weeks produces diminishing anabolic return and a steep rise in hepatobiliary risk indicators.

Researchers in this area generally treat methandrostenolone as a companion to testosterone rather than a standalone agent. Solo oral-only protocols are described in the older literature but are associated with unfavorable endocrine profiles — pronounced suppression of endogenous testosterone without the exogenous replacement that a testosterone-based protocol provides, leaving the subject hypogonadal throughout the oral phase and beyond.

Hepatotoxicity and Lipid Effects

The 17-alpha-methyl group is directly responsible for methandrostenolone's hepatic signature. The modification that permits oral bioavailability also makes the molecule resistant to normal hepatic conjugation pathways, prolonging intrahepatic residence time. Published case reports and small prospective series consistently describe three overlapping hepatic patterns: transaminase elevation (ALT often 2–5× upper limit of normal at moderate doses), cholestatic jaundice in a minority of subjects, and — rarely — peliosis hepatis, a vascular lesion characterized by blood-filled hepatic cysts that has been reported across the 17-alkylated oral class.

The lipid profile is the other dominant concern. Methandrostenolone administration has been reported to produce sharp, reproducible suppression of HDL-cholesterol, often in the range of 30–60% from baseline within weeks, alongside LDL elevation. A representative mechanism involves induction of hepatic lipase, which clears HDL particles from circulation. The resulting shift in the LDL:HDL ratio is substantial and, in prospective studies of AAS-using athletes, has been correlated with surrogate markers of accelerated atherogenesis such as increased carotid intima-media thickness.

Blood-pressure elevation is reported consistently, driven by a combination of sodium and water retention (via the compound's estrogenic metabolite and mineralocorticoid effects) and the lipid-profile shifts noted above. Resting systolic pressures 10–20 mmHg above baseline are common in the observational literature even in subjects who were normotensive pre-protocol.

Estrogen Management and Ancillary Support

Because aromatization to 17α-methylestradiol is the proximate cause of the water retention, gynecomastia risk, and a portion of the blood-pressure rise seen with methandrostenolone, aromatase inhibitor (AI) pairing is standard in the documented protocols. Anastrozole is the most frequently cited companion agent in the self-report literature, typically dosed at 0.25–0.5 mg every other day during the oral phase and titrated against serum estradiol rather than used at a fixed dose.

Importantly, 17α-methylestradiol binds the estrogen receptor directly and is not itself a substrate for aromatase. This means that AI therapy reduces the formation of new methylestradiol but does not clear already-formed metabolite — a pharmacological quirk that explains why some subjects in case reports continue to show estrogenic symptoms despite apparently adequate AI dosing. Selective estrogen receptor modulators (tamoxifen, raloxifene) are sometimes added in that scenario to block receptor-level activity.

Hepatic support is the second consistent theme in the protocol literature, though evidence quality varies. N-acetylcysteine (NAC), typically 600–1200 mg/day, is the most commonly cited adjunct and has modest supporting data for attenuating drug-induced hepatocyte injury via glutathione precursor activity. Tauroursodeoxycholic acid (TUDCA), 250–500 mg twice daily, is described in the case-report literature as reducing cholestatic markers during 17-alkylated oral use, though controlled data in this specific context remain limited. Milk thistle (silymarin) is frequently included despite relatively weak efficacy data.

Dietary factors receive attention as well. Low-saturated-fat, high-fiber, plant-sterol-enriched dietary patterns are commonly prescribed during the oral phase to partially counteract the HDL suppression, and alcohol is typically discontinued given the additive hepatic load. Omega-3 supplementation at 3–4 g/day of combined EPA+DHA is cited for its lipid-profile and blood-pressure effects.

Why Short Cycles

The six-week ceiling on methandrostenolone exposure reflects a convergence of pharmacological and clinical pressures that is unusual even within the 17-alkylated oral class.

The first is hepatic. Hepatocyte damage during methylated-oral exposure appears to be partly cumulative and partly time-dependent; transaminase trajectories in published case series typically show a continuous upward slope through weeks 4–6 rather than plateauing. Discontinuation at the six-week mark is associated in follow-up reports with return of liver enzymes to baseline within 4–8 weeks, whereas protocols extending to 10–12 weeks have been associated with more persistent hepatic signal.

The second is lipid-related. The HDL-suppression magnitude seen with methandrostenolone tracks roughly linearly with cumulative exposure over the first month of use. Prospective studies examining longer exposure windows have described HDL suppression that persists after discontinuation — weeks to months in some subjects — suggesting that extended oral phases damage the lipid-handling machinery beyond what is explained by current plasma levels alone.

The third is anabolic return. Reported strength and lean-mass gain curves during methandrostenolone exposure are steepest in weeks 1–3 and flatten noticeably by week 5, consistent with receptor saturation kinetics and the compound's relatively modest direct AR affinity. Beyond six weeks, additional risk is accepted for little additional anabolic signal.

For these reasons, the research-chemistry convention is a clear boundary: 4 weeks as a conservative kickstart, 6 weeks as an upper limit, and a defined break before any reintroduction. Subjects returning to methandrostenolone after a full set of recovered labs (liver panel, lipid panel, estradiol, total and free testosterone) appear in the follow-up literature; subjects who stack repeated oral phases without washout do not fare as well.

Open Questions

Several aspects of methandrostenolone's profile remain incompletely characterized in the peer-reviewed literature. The mechanism driving the persistence of HDL suppression after discontinuation has not been fully resolved — whether it reflects sustained hepatic lipase induction, altered cholesterol-efflux protein expression, or something else. The relative hepatotoxicity ranking of methandrostenolone against other 17-alkylated orals remains contested; case-report density favors oxymetholone as the heaviest hitter and oxandrolone as the lightest, but prospective head-to-head work is sparse. Long-term cardiovascular outcome data in former users — as opposed to surrogate-marker data during use — remains an area where published cohorts are small and follow-up windows short. Researchers interested in the compound's place within a broader protocol will find testosterone, anastrozole, and 17-alkylated oral pharmacology the most productive adjacent literatures to follow.